Prepare to overcome your supply issues in 2022 by developing a high-performing supply chain for the cGMP chemicals critical to your biologic manufacturing. Download now!
A combination of Bayer’s androgen receptor inhibitor Nubeqa plus standard of care trumped standard care alone at prolonging the lives of men with metastatic hormone-sensitive prostate cancer.
The PerkinElmer Lead Discovery Premium Biotech Bundle empowers you to find and understand trends and outliers in your data to ensure successful candidate selection. On the AWS Cloud, affordable, easy to deploy. Learn more.
The BeyondSpring roller coaster has plunged downward again. While BeyondSpring wowed investors with its phase 3 lung cancer data in August, the FDA found less to like in another indication, rejecting the drug on the grounds that the single registrational trial was too flimsy to show the drug’s benefit.
The prostate cancer-focused technology’s FDA clearance comes just a month after Insightec racked up yet another regulatory approval for its Exablate Neuro system.
Provider groups slammed the House for not delaying nearly 10% in Medicare payment cuts in a must-pass spending bill, as concerns mount the cuts could go through next month.
CAR-T cells to treat cancer have precious little time to proliferate in the body, which often limits their anti-tumor efficacy. A team at the Curie Institute pinpointed the protein SOCS1 as an inhibitor of CAR-T expansion and survival and suggested it could be targeted to improve T-cell therapies.
Sandoz is recalling one lot of enoxaparin sodium injection single dose syringes after part of the batch was exposed to high temperatures during shipping. The balmy conditions may have “significantly impacted” the drug’s effectiveness, Sandoz said.
In one of the biggest funding rounds for a European biotech ever, Czech Republic cancer company Sotio Biotech has grabbed a huge 280 million euro ($316 million) raise.
The study is testing two separate devices that aim to work together to keep the heart from beating too fast or too slow and communicate wirelessly and require no electric leads to be threaded into the heart muscle. The study’s first two patients underwent the procedure at the Cleveland Clinic.
Even as the healthcare system drives toward innovation, it remains too "fragmented" to achieve sustained and substantial improvements, said UnitedHealth Group CEO Andrew Witty.
Sixty-seven novel therapies entered China’s national reimbursement drug list for the first time and offered an average 61.7% discount through negotiations with the government. Here we summarize some of the most important movements from the likes of Biogen, Fosun-Kite, Eli Lilly, AstraZeneca and more.
In studies submitted to the FDA for authorization, Sound's software was used to monitor patients with chronic respiratory pulmonary disease, asthma, congestive heart failure, anxiety and more.
AviadoBio has come flying out the traps surrounded by A-list names. Incubated at F-Prime Capital and Johnson & Johnson’s JJDC, AviadoBio exited stealth with $80 million from backers such as New Enterprise Associates and a C-suite led by Novartis veteran Lisa Deschamps.
